Ongoing studies include a phase 3 trial for Hr-positive, HER2-negative metastatic breast cancer (TROPiCS-02, NCT03901339) and multiple trials evaluating SG as a single-agent or in combination with other therapies for TNBC and HER2-negative breast cancer, including in the curative setting. This evidence concerns the gene ERBB2 and breast carcinoma.